

Safety of sodium-glucose cotransporter-2 inhibitors in patients with CKD and type 2 diabetes: population-based US cohort study Fu, E.L.; D'Andrea, E.; Wexler, D.J.; Patorno, E.; Paik, J.M.

Citation

Fu, E. L., D'Andrea, E., Wexler, D. J., Patorno, E., & Paik, J. M. (2023). Safety of sodium-glucose cotransporter-2 inhibitors in patients with CKD and type 2 diabetes: population-based US cohort study. *Clinical Journal Of The American Society Of Nephrology*, *18*(5), 592-601. doi:10.2215/CJN.00000000000115

Version:Publisher's VersionLicense:Creative Commons CC BY-NC-ND 4.0 licenseDownloaded from:https://hdl.handle.net/1887/3762078

Note: To cite this publication please use the final published version (if applicable).

Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study

Edouard L. Fu^(b),¹ Elvira D'Andrea^(b),¹ Deborah J. Wexler^(b),² Elisabetta Patorno,¹ and Julie M. Paik^(b),^{1,3,4}

Abstract

Background Limited information exists regarding the safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with CKD treated in routine care. We evaluated the safety of SGLT2i in patients with CKD and type 2 diabetes treated in US routine practice.

Methods Using claims data from Medicare and two large US commercial databases (April 2013–December 2021), we included 96,128 adults with CKD stages 3–4 and type 2 diabetes who newly filled prescriptions for SGLT2i versus glucagon-like peptide-1 receptor agonists (GLP-1RA). Safety outcomes included diabetic ketoacidosis (DKA), lower limb amputations, nonvertebral fractures, genital infections, hypovolemia, AKI, hypoglycemia, and severe urinary tract infections (UTIs). Hazard ratios (HRs) and incidence rate differences per 1000 person-years were estimated after 1:1 propensity score matching, adjusted for >120 baseline characteristics.

Results Compared with GLP-1RA, SGLT2i initiators had a higher risk of nonvertebral fractures (HR, 1.30 [95% confidence interval (CI), 1.03 to 1.65]; incidence rate difference, 2.13 [95% CI, 0.28 to 3.97]), lower limb amputations (HR, 1.65 [95% CI, 1.22 to 2.23]; incidence rate difference, 2.46 [95% CI, 1.00 to 3.92]), and genital infections (HR, 3.08 [95% CI, 2.73 to 3.48]; incidence rate difference, 41.26 [95% CI, 37.06 to 45.46]). Similar risks of DKA (HR, 1.07 [95% CI, 0.74 to 1.54]; incidence rate difference, 0.29 [95% CI, -0.89 to 1.46]), hypovolemia (HR, 0.99 [95% CI, 0.86 to 1.14]; incidence rate difference, 0.20 [95% CI, -2.85 to 3.25]), hypoglycemia (HR, 1.08 [95% CI, 0.92 to 1.26]; incidence rate difference, 1.46 [95% CI, -1.31 to 4.23]), and severe UTI (HR, 1.02 [95% CI, 0.87 to 1.19]; incidence rate difference, -6.75 [95% CI, -13.69 to 0.20]).

Conclusions In US patients with CKD and type 2 diabetes receiving routine care, SGLT2i use was associated with higher risks of genital infections and potentially lower limb amputations and nonvertebral fractures.

CJASN 18: 592-601, 2023. doi: https://doi.org/10.2215/CJN.00000000000115

Introduction

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are recommended as first-line therapy in patients with type 2 diabetes and CKD who have an eGFR ≥ 20 ml/min per 1.73 m².^{1,2} Although randomized controlled trials have shown the cardiovascular and renoprotective effects of SGLT2i in patients with diabetic kidney disease,^{3,4} their uptake in routine clinical practice has been slow: Recent studies show that as few as 6% of patients with CKD and type 2 diabetes are currently prescribed SGLT2i in the United States.^{5,6} This is especially concerning because these patients are at high risk for cardiovascular disease and kidney disease progression.^{7,8}

The slow clinical adoption of SGLT2i may partly be due to concerns about potential adverse effects, including diabetic ketoacidosis (DKA), fractures, amputations, and urogenital infections.^{9–11} These safety events are especially important as patients with CKD have a higher baseline risk of fractures and lower limb amputations than the non-CKD population, due to disorders in mineral and bone metabolism and high prevalence of risk factors for foot ulceration.^{12–15}

Currently, there is a paucity of safety data on SGLT2i in patients with CKD and type 2 diabetes. Clinical trials are generally underpowered to assess rare but potentially severe side effects.^{3,4} They also include highly selected patient populations with different characteristics from those who receive SGLT2i in routine care^{16,17} and apply monitoring protocols to lower the risk of adverse effects which may not be adopted in routine practice. We therefore aimed to comprehensively investigate the safety profile of SGLT2i in routinely cared patients with CKD and type 2 diabetes using three nationwide US databases.

Methods

Data Source

We used data from three large US health insurance databases: Optum's deidentified Clinformatics Data Mart Database (CDM), IBM MarketScan, and

¹Division of Pharmacoepidemiology and Pharmacoeconomics. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts ²Diabetes Center. Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts ³Division of Renal (Kidney) Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts ⁴New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts

Correspondence:

Dr. Julie M. Paik, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 1620 Tremont Street, BC-3012C, Boston, MA 02120. Email: jmpaik@bwh. harvard.edu Medicare Fee-for-Service Parts A, B, and D. CDM and IBM MarketScan include a national commercially insured US population. Medicare is a federal health insurance program providing health care coverage for US residents 65 years or older or younger than 65 years with disabilities. The databases contain deidentified, longitudinal, individual-level data on health care use, inpatient and outpatient diagnoses, diagnostic tests and procedures, outpatient laboratory results (approximately 45% of patients in CDM and 5%–10% in IBM MarketScan), and pharmacy dispensing of drugs. This study was approved by the Mass General Brigham Institutional Review Board, and signed data license agreements were in place for all data sources.

Study Design and Study Population

We conducted an active comparator, new-user cohort study of patients 18 years or older (65 years or older for Medicare) who newly initiated an SGLT2i (i.e., empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin) or a glucagon-like peptide-1 receptor agonist (GLP-1RA) (i.e., liraglutide, dulaglutide, semaglutide, exenatide, albiglutide, and lixisenatide) between April 2013, when the first SGLT2i was released in the United States, and the end of available data (April 2021 in CDM, December 2019 in Medicare Fee-for-Service, and December 2020 in IBM MarketScan) (Supplemental Figure 1). New initiation was defined as a filled prescription for SGLT2i or GLP-1RA, with no previous filled prescriptions of either drug in the previous 365 days. We used GLP-1RA as the active comparator¹⁸⁻²⁰ because GLP-1RA has similarly been shown to reduce cardiovascular events in randomized trials.²¹ Both drugs had similar clinical indications during the study period (i.e., second-line or third-line glucoselowering drugs for patients at high cardiovascular risk) and similar temporal trends in use.5,22-24 To be eligible, patients were required to have at least 12 months of continuous health insurance enrollment preceding the cohort entry date as well as diagnoses for CKD and type 2 diabetes. CKD was defined as at least one inpatient or two outpatient diagnosis codes for CKD stages 3-5, and no data on eGFR were used (Supplemental Table 1); the definition was based on a previously validated algorithm that showed sufficient accuracy to identify a population with CKD stages 3-5 (positive predictive value >80%).²⁵ We excluded individuals with a history of type 1 diabetes, secondary or gestational diabetes, kidney failure, nursing home admission, organ transplant, pancreatitis, cirrhosis, acute hepatitis, or multiple endocrine neoplasia type 2 (Supplemental Table 1).

Drug Exposure and Follow-Up

The study exposure was filled prescription for SGLT2i or GLP-1RA. Follow-up began on the day after cohort entry and continued in an "as-treated" approach until the earliest of treatment discontinuation or switch to a drug in the comparator class, outcome occurrence, death, end of continuous health plan enrollment, or end of available data, whichever occurred first. Discontinuation was defined as no prescription refill for the index exposure within 30 days after the termination of the last prescription's supply. We chose an as-treated follow-up approach as primary analysis to address the high rate of treatment discontinuation in routine care,²⁶ which reduces the exposure misclassification that occurs when intention-to-treat analyses are applied in observational studies.²⁰

Study Outcomes

Safety outcomes included DKA, nonvertebral fractures, lower limb amputations, genital infections, hypovolemia, severe hypoglycemia, AKI, and severe urinary tract infections (UTI). We selected these outcomes on the basis of potential safety signals of SGLT2i previously identified in randomized trials or observational studies. The outcomes were identified using validated International Classification of Diseases-9/10-CM procedural and diagnosis codes (Supplemental Table 2). Validation studies for the claimsbased algorithms for DKA, nonvertebral fractures, severe hypoglycemia, and AKI have shown positive predictive values >80%.^{27–31} We adapted definition codes from previous studies for safety outcomes without validation studies (genital infections, lower limb amputations, and severe UTI).^{32–34}

Covariates

Baseline characteristics were measured during 365 days before or on cohort entry. These included demographics, comorbid conditions, diabetes-specific complications, use of diabetes and non–diabetes-related drugs, and measures of health care use (Supplemental Table 1). To address potential confounding by frailty, we also used a claims-based frailty index.³⁵ Laboratory results were available for approximately 15% of the overall population (approximately 45% of patients in CDM and 5%–10% in IBM MarketScan). Race was self-reported in the claims data sources and not specifically collected for research purposes. There were no missing data for the other covariates (the absence of a diagnosis or procedure code was interpreted as the absence of a particular condition).

Statistical Analyses

We used 1:1 propensity score matching using the nearest neighbor method with a caliper of 0.01 of the propensity score to adjust for confounding.³⁶ We estimated the probability of receiving SGLT2i versus GLP-1RA as a function of >120 pre-exposure covariates using multivariable logistic regression. All covariates listed in Supplemental Table 1 were included in the propensity score model except for laboratory results, which were only available in a subset of patients. Covariate balance before and after matching was assessed using standardized mean differences.^{37,38} Balance in laboratory results was also inspected to assess potential residual confounding by unmeasured factors because laboratory results were not included in the propensity score. For all outcomes, we calculated propensity score-matched numbers of events, incidence rates, incidence rate differences, and hazard ratios (HRs). The HRs and incidence rate differences with their 95% confidence intervals (CIs) were estimated in each data source and then pooled using a fixed effects meta-analysis. HRs were estimated using cause-specific Cox regression, and incidence rate differences using generalized linear regression with identity link function and normal error distribution.³⁹ We constructed cumulative incidence function plots with the Aalen-Johansen estimator, which does not overestimate

risks in the presence of the competing risk of death.⁴⁰ Analyses were performed using R version 3.6.2 and Aetion Evidence Platform v4.53.

Subgroup, Sensitivity, and Post Hoc Analyses

We performed subgroup analyses in the following prespecified strata: age (65-74 versus 75 years or older), sex, cardiovascular disease, heart failure, metformin use, insulin use, and sulfonylurea use. Within each subgroup, we re-estimated the propensity score and reperformed 1:1 propensity score matching. We also performed multiple sensitivity analyses. First, we defined treatment discontinuation as no prescription refill within 60 days (instead of 30 days). Second, to investigate the influence of informative censoring, we applied an intention-to-treat follow-up approach, where follow-up was continued for a maximum of 6 and 12 months regardless of treatment discontinuation or switch. We also performed three post hoc analyses. First, to address the potential for unmeasured confounding associated with risk for recurrence, we excluded individuals with prior nonvertebral fractures and lower limb amputations. Second, to investigate a potential effect of GLP-1RA on some of the study outcomes, we also compared SGLT2i with dipeptidyl peptidase-4 inhibitor (DPP4i). Third, we investigated the association between SGLT2i versus GLP-1RA with different types of nonvertebral fractures (hip and femur, humerus, pelvis, radius, and ulna).

Results

Study Population

We included a total of 96,128 individuals with CKD and type 2 diabetes, of whom 32,192 initiated SGLT2i and 63,936 GLP-1RA (Supplemental Figure 2). Although reasonably well balanced in baseline characteristics before propensity score matching, compared with GLP-1RA initiators, the SGLT2i group was slightly older, more likely to be male, and less likely to have obesity or CKD stage 4 (Table 1, Supplemental Table 3). They were also more likely to use metformin and DPP4i, but less likely to use insulin. After 1:1 propensity score matching 28,847 SGLT2i initiators to 28,847 GLP-1RA initiators, differences in patient characteristics were well balanced across treatment groups (see Supplemental Tables 4-6 for baseline characteristics in each database, Supplemental Figure 3 for propensity score distributions before and after propensity score matching). Laboratory results were also well balanced, except for a small difference in eGFR (2.6 ml/min per 1.73 m² higher for SGLT2i users) among the subset with available data. In the matched cohort, the mean age was 72 years, 56% were men, and 64% were White. Furthermore, 25% had heart failure, 90% had stage 3 CKD, 41% used metformin, and 27% used insulin. Among SGLT2i agents, empagliflozin was most commonly used (51%), followed by canagliflozin (35%) and dapagliflozin (14%) (Supplemental Table 7). The most used GLP-1RA agents were dulaglutide (40%), liraglutide (33%), and semaglutide (13%).

Safety of SGLT2i versus GLP-1RA

The mean on-treatment follow-up time was 7.5 months (median, 4.0 months). Most patients were censored due to treatment discontinuation (62%) or end of study period (23%) (Supplemental Table 8). In the 1:1 propensity

score-matched cohort, SGLT2i compared with GLP-1RA were associated with a higher risk of nonvertebral fractures (HR, 1.30 [95% CI, 1.03 to 1.65]; incidence rate difference, 2.13 [95% CI, 0.28 to 3.97] events per 1000 person-years), lower limb amputations (HR, 1.65 [95% CI, 1.22 to 2.23]; incidence rate difference, 2.46 [95% CI, 1.00 to 3.92]), and genital infections (HR, 3.08 [95% CI, 2.73 to 3.48]; incidence rate difference, 41.26 [95% CI, 37.06 to 45.46]) (Figure 1). Similar risks of DKA (HR, 1.07 [95% CI, 0.74 to 1.54]; incidence rate difference, 0.29 [95% CI, -0.89 to 1.46]), hypovolemia (HR, 0.99 [95% CI, 0.86 to 1.14]; incidence rate difference, 0.20 [95% CI, -2.85 to 3.25]), hypoglycemia (HR, 1.08 [95% CI, 0.92 to 1.26]; incidence rate difference, 1.46 [95% CI, -1.31 to 4.23]), and severe UTI (HR, 1.02 [95% CI, 0.87 to 1.19]; incidence rate difference, 0.35 [95% CI, -2.51 to 3.21]) were observed, and a lower AKI risk (HR, 0.93 [95% CI, 0.87 to 0.99]; incidence rate difference, -6.75 [95% CI, -13.69 to 0.20]) was observed. Cumulative incidence curves (Figure 2) showed that the divergence for lower limb amputations, genital infections, and nonvertebral fractures occurred within the first 6 months of follow-up.

Subgroup, Sensitivity, and Post Hoc Analyses

Higher risks for lower limb amputations, genital infections, and nonvertebral fractures for SGLT2i versus GLP-1RA were observed across most subgroups of age, sex, cardiovascular disease, heart failure, and use of metformin, sulfonylurea, or insulin, although confidence intervals were wider (Figure 3).

The results were consistent when using a 60-day grace period after treatment discontinuation or switch (Supplemental Table 9). In both 180-day and 365-day intention-to-treat analyses, we observed elevated risks for genital infections (HR, 2.72; 95% CI, 2.40 to 3.09) and lower limb amputations (HR, 1.57; 95% CI, 1.13 to 2.19), but not for nonvertebral fractures (HR, 1.09; 95% CI, 0.82 to 1.44) (Supplemental Tables 10 and 11). Risks associated with SGLT2i versus GLP-1RA remained consistent after excluding individuals with prior nonvertebral fractures or lower limb amputations, with HRs of 1.32 (95% CI, 1.04 to 1.68) for nonvertebral fractures and 1.89 (95% CI, 1.34 to 2.67) for lower limb amputations (Supplemental Table 12). When comparing SGLT2i with DPP4i, the HR remained elevated for genital infections (HR, 2.75; 95% CI, 2.41 to 3.15), but not for lower limb amputations (HR, 1.13; 95% CI, 0.82 to 1.56) and fractures (HR, 0.87; 95% CI, 0.68 to 1.12) (Supplemental Table 12). The higher fracture risk for SGLT2i compared with GLP-1RA was driven by a higher risk of hip and femur fractures (HR, 1.62; 95% CI, 1.14 to 2.30) (Supplemental Table 13).

Discussion

In this large population-based study of individuals with CKD and type 2 diabetes treated in routine care, we found that SGLT2i use, as compared with GLP-1RA use, was associated with higher risks of lower limb amputations, genital infections, and nonvertebral fractures. No noticeable differences were observed for the other safety outcomes, including DKA, hypovolemia, hypoglycemia, and severe UTI. Findings were consistent across multiple sensitivity and subgroup analyses, although

 Table 1. Selected baseline characteristics of patients with CKD and type 2 diabetes initiating treatment with SGLT2i versus GLP-1RA, before and after 1:1 propensity score matching in the pooled cohort

	Before Prope	ensity Score Ma	atching	After 1:1 Prop	pensity Score M	latching
Characteristic	SGLT2i	GLP-1RA	SMD	SGLT2i	GLP-1RA	SMD
Total	32,192	63,936		28,847	28,847	
Demographics			0.17			0.00
Age, mean (SD)	73 (7) 19 452 (57)	71 (7) 22 0(1 (E0)	-0.16	72 (7)	72 (7)	0.00
Men, \mathcal{H} (%) Base (atheniaity ^a \mathcal{H} (9)	18,452 (57)	32,061 (50)	-0.14	16,080 (56)	16,070 (56)	0.00
Acian	1719 (5)	1842 (3)	-0.12	1202 (4)	1162 (4)	-0.01
Black	3184(10)	6442(10)	0.01	2840(10)	2874(10)	0.01
Hispanic	2207 (7)	3650 (6)	-0.05	1888 (7)	1836 (6)	0.00
Other	1497 (5)	2528 (4)	-0.03	1280 (4)	1276 (4)	0.00
White	20,135 (63)	42,214 (66)	0.07	18,444 (64)	18,506 (64)	0.01
Burden of comorbidities			0.00		104 (2.10)	0.01
Erailty same man (SD) ^c	4.07 (2.48)	4.14 (2.38)	0.03	4.03 (2.45)	4.06 (2.43)	0.01
Comorbidities u (%)	0.20 (0.06)	0.21 (0.06)	0.17	0.21 (0.06)	0.21 (0.06)	0.00
Hypertension	30,996 (96)	61,926 (97)	0.03	27,797 (96)	27,758 (96)	-0.01
Hyperlipidemia	28,753 (89)	57,081 (89)	0.00	25,732 (89)	25,678 (89)	-0.01
Cardiovascular disease ^d	19,204 (60)	37,233 (58)	-0.03	16,935 (59)	16,962 (59)	0.00
Acute myocardial infarction	1541 (5)	2395 (4)	-0.05	1222 (4)	1249 (4)	0.00
Coronary atherosclerosis	13,546 (42)	25,324 (40)	-0.05	11,823 (41)	11,955 (41)	0.01
Heart failure	8332 (26)	16,428 (26)	0.00	7236 (25)	7267 (25)	0.00
Ischemic stroke Peripheral arterial disease	4814 (15)	9054 (14)	-0.02	4218(15) 5261(10)	4217 (15) 5425 (10)	0.00
AKI	5362(17)	12,039 (19)	0.00	4835 (17)	4896 (17)	0.01
CKD stage 3	29.339 (91)	53.125 (83)	0.24	26.086 (90)	26.104 (91)	0.00
CKD stage 4	2853 (9)	10,811 (17)	0.24	2761 (10)	2743 (10)	0.00
Urinary tract infection	5683 (18)	13,376 (21)	0.08	5228 (18)	5208 (18)	0.00
Kidney and urinary stone	2315 (7)	4982 (8)	0.02	2095 (7)	2093 (7)	0.00
Edema	6601 (21)	16,047 (25)	0.11	6102 (21)	6107 (21)	0.00
COPD	5554 (17)	11,274 (18)	0.01	4951 (17)	5028 (17)	0.01
Asthma	3080 (10)	6889 (11) 1500 (2)	0.04	2809(10)	2848 (10)	0.01
Factures	2175(7)	1390 (3)	0.03	1943(7)	1972(7)	0.01
Diabetes-related conditions, n (%)	2175 (7)	4725 (7)	0.02	1)45 (7)	1)/2 (/)	0.00
Diabetic kidney disease	21,765 (68)	45,445 (71)	0.08	19,501 (68)	19,570 (68)	0.00
Diabetic retinopathy	5737 (18)	13,610 (21)	0.09	5265 (18)	5225 (18)	-0.01
Diabetic neuropathy	11,280 (35)	25,859 (40)	0.11	10,324 (36)	10,452 (36)	0.01
Diabetes with peripheral circulatory disorders	796 (3)	1684 (3)	0.01	716 (3)	732 (3)	0.00
Diabetic foot	1389 (4)	3677 (6)	0.07	1300(5)	1309 (5)	0.00
Lower limb amputation	552 (1) 5770 (18)	998 (2) 11 834 (19)	0.04	5089 (18)	557 (1) 5137 (18)	0.01
Diabetic ketoacidosis	121(0.4)	259 (0.4)	0.02	104(0.4)	100(0.3)	-0.01
No. of distinct medications, mean (SD)	16 (6)	17 (7)	0.16	16 (6)	16 (6)	0.01
Diabetes medications on day of entry to cohort					~ /	
No. of antidiabetes drugs, mean (SD)	2 (1)	2 (1)	-0.11	2 (1)	2 (1)	0.00
Metformin, n (%)	14,063 (44)	18,617 (29)	-0.31	11,887 (41)	11,455 (40)	-0.03
Sulfonylureas, n (%)	12,374 (38)	22,349 (35)	-0.07	11,033 (38)	11,377 (39)	0.02
DPP-4 inhibitors, n (%)	9783 (30)	14,164 (22) 26 224 (41)	-0.19	8404 (29)	7757 (27)	-0.05
Other medication use n (%)	7400 (23)	20,224 (41)	0.39	7378 (20)	7934 (20)	0.04
ACE inhibitors or angiotensin II receptor blockers	26,282 (82)	51,546 (81)	-0.03	23,536 (82)	23,508 (82)	0.00
Beta blockers	19,572 (61)	39,597 (62)	0.02	17,482 (61)	17,501 (61)	0.00
Calcium channel blockers	14,467 (45)	29,410 (46)	0.02	12,985 (45)	12,880 (45)	-0.01
Loop diuretics	10,711 (33)	25,734 (40)	0.14	9780 (34)	9828 (34)	0.00
Statins	27,347 (85)	54,022 (85)	-0.01	24,414 (85)	24,383 (85)	0.00
Antiplatelets	6285 (20)	11,366 (18)	-0.04	5439 (19) 4205 (15)	5425 (19)	0.00
Anticoaguiants Oral corticostoroids	4948 (15) 6459 (20)	9767 (15)	0.00	4395 (15) 5771 (20)	4381 (15)	0.00
Antiosteoporosis agents	1754 (5)	3017(5)	-0.03	1475(5)	1480 (5)	0.01
Opioids	11.387 (35)	25.951 (41)	0.11	10.486 (36)	10.651 (37)	0.00
Health care utilization markers, mean (SD)						
No. of hospital days	1.66 (4.99)	1.72 (5.31)	-0.01	1.66 (5.41)	1.64 (5.19)	0.00
No. of emergency department visits	0.86 (1.99)	0.92 (2.04)	0.03	0.86 (1.97)	0.87 (2.09)	0.00
No. of internist visits	22.42	21.43	-0.04	22.03	22.18	0.01
No. of cardiologist visits	(26.93) 5.85 (10.90)	(20.10) 5 16 (9 65)	_0.07	(26.52)	(26.73) 5 52 (10.42)	0.00
No. of endocrinologist visits	1.70 (7 10)	2.46 (7.40)	0.10	1.81(7.39)	1.80(6.00)	-0.00
No. of nephrologist visits	1.90 (5.82)	2.51 (6.32)	0.10	1.97 (6.02)	1.97 (5.32)	0.00

Table 1. (Continued)

Chamatasiatia	Before Prope	ensity Score Ma	atching	After 1:1 Prop	pensity Score N	latching
Characteristic	SGLT2i	GLP-1RA	SMD	SGLT2i	GLP-1RA	SMD
No. of HbA1c tests ordered No. of metabolic or creatinine tests ordered No. of microalbuminuria/proteinuria tests ordered	3.00 (1.57) 4.86 (3.78) 1.58 (1.58)	3.12 (1.57) 5.22 (3.79) 1.70 (1.62)	0.08 0.10 0.07	3.02 (1.57) 4.88 (3.72) 1.60 (1.59)	3.02 (1.55) 4.90 (3.57) 1.59 (1.54)	$0.00 \\ 0.01 \\ -0.01$

SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; SMD, standardized mean difference; *n*, number of patients; COPD, chronic obstructive pulmonary disease; No., number of; DPP-4, dipeptidyl peptidase-4; ACE, angiotensin-converting enzyme; HbA1c, hemoglobin A1c.

Pooled across Clinformatics Data Mart and Medicare databases.

^bBased on Gagne et al.⁵¹

Based on Kim et al.35

^dCardiovascular disease was defined as a composite of myocardial infarction, stable angina, acute coronary syndrome, coronary atherosclerosis, history of coronary procedure, heart failure, ischemic stroke, and peripheral vascular disease.



Figure 1. Number of events, incidence rates, incidence rate differences, and hazard ratios for safety outcomes, comparing SGLT2i versus GLP-1RA after 1:1 propensity score matching. CI, confidence interval; GLP-1RA, glucagon-like peptide-1 receptor agonist; HR, hazard ratio; IR, incidence rate; PY, person-year; SGLT2i, sodium-glucose cotransporter-2 inhibitors; UTI, urinary tract infection.

we did not identify an elevation in risk of lower limb amputations or fractures associated with SGLT2i when compared with the DPP4i class.

To the best of our knowledge, this is the first study to comprehensively assess the safety profile of SGLT2i in routine care patients with CKD and type 2 diabetes. Assessing the incremental risk of safety outcomes such as fractures, lower limb amputations, and AKI associated with SGLT2i is important because the baseline risk of these complications in patients with CKD is markedly higher compared with adults without CKD.^{12–15,41} The unclear safety profile of these drugs may be one of the contributors to the slow uptake of SGLT2i among patients with CKD,^{5,6} despite clinical practice guidelines recommending these drugs as first-line therapy.^{1,42}

Our results suggest potential higher risks for lower limb amputations and nonvertebral fractures in routinely cared populations associated with the use of SGLT2i, which were not observed in randomized trials investigating SGLT2i in patients with CKD and type 2 diabetes.^{3,4} The absolute risk increase for these safety outcomes was small: 2.1 more lower limb amputations and 2.5 more fractures per 1000 people receiving SGLT2i versus GLP-1RA. In addition, SGLT2i were associated with 41 more genital infections per 1000 people. These findings need to be contextualized in light of the benefits of SGLT2i in this population because patients with CKD are at high cardiovascular and kidney risk. The reduction in the composite outcome of doubling of serum creatinine, kidney failure, cardiovascular, or kidney death was 18 events per 1000 person-years in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial.⁴ In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, the absolute reduction was 29 events per 1000 person-years for the composite of 50% eGFR decline, kidney failure, cardiovascular, and kidney death.³ Finally, in the Study of Heart and Kidney Protection with Empagliflozin (EMPA-KIDNEY), the absolute reduction was 21 events per 1000 person-years for the composite of progression of kidney disease (defined as kidney failure, sustained eGFR <10 ml/min per 1.73 m², sustained 40% eGFR decline, or death from kidney causes) or cardiovascular death.

Our findings of an elevated risk of lower limb amputations are similar to those of the CANagliflozin cardio-Vascular Assessment Study (CANVAS) Program, which found higher risks for canagliflozin versus placebo



Figure 2. Cumulative incidence curves comparing SGLT2i versus GLP-1RA after 1:1 propensity score matching for specific outcomes. (A) Nonvertebral fractures, (B) genital infections, (C) diabetic ketoacidosis, and (D) lower limb amputations. DKA, diabetic ketoacidosis; LLA, lower limb amputations.

(incidence rate 6.3 versus 3.4 per 1000 patient-years; HR, 1.97; 95% CI, 1.41 to 2.75) among patients with type 2 diabetes at high cardiovascular risk.⁴³ Consistent with our findings, EMPA-KIDNEY found a trend toward a higher risk for lower limb amputations (incidence rate 4.3 versus 2.9 per 1000 patient-years; HR, 1.43; 95% CI, 0.80 to 2.57).44 No elevated risks were observed in lower limb amputations in two other SGLT2i trials in patients with CKD. CREDENCE randomized 4401 patients with an eGFR between 30 and 90 ml/min per 1.73 m² and an albumin-to-creatinine ratio (ACR) of 300-5000 mg/g to canagliflozin versus placebo, and incidence rates were 12.3 versus 11.2 events per 1000 person-years, corresponding to a HR of 1.11 (95% CI, 0.79 to 1.56).⁴ However, following the results of CANVAS, a protocol amendment was issued in May 2016 that asked investigators "to examine patient's feet at each trial visit and temporarily interrupt the assigned treatment in patients with any active condition that might lead to amputation."4 Such monitoring practices may have contributed to the null finding observed in CREDENCE and may not be generally applied in routine clinical care. DAPA-CKD, which randomly assigned 4304 patients with an eGFR of 25-75 ml/min per 1.73 m² and ACR between 200 and 500 mg/g to dapagliflozin or placebo, also found no difference for amputations (incidence rate 1.6 versus 1.8 per 1000 patient-years; HR, 0.90; 95% CI, 0.57 to 1.41),³ but found a much lower incidence rate than CANVAS, CREDENCE, or our study. Besides monitoring practices, differences in amputation risk may also be explained by differences in population characteristics: Our study population was on average 10 years older than those in CREDENCE and DAPA-CKD and had higher prevalence of cardiovascular disease (59% versus 37% in DAPA-CKD and 50% in CREDENCE). However, when comparing SGLT2i with the DPP4i class, the higher risk for lower limb amputations was attenuated. This may be due to larger confounding with DPP4i than GLP-1RA.

The higher risk of nonvertebral fractures in our study for SGLT2i versus GLP-1RA was similar in magnitude to that observed in the CANVAS Program (incidence rate 15.4 versus 11.9 per 1000 patient-years; HR, 1.26; 95% CI, 1.04 to 1.52).⁴³ However, higher risks were not observed in CREDENCE (incidence rate 11.8 versus 12.1 per 1000

A Bone fractures		SGLT2i							
Population	Number of persons/arm	Number (IR/1,	of events 000 PY)	Ir	Incidence rate difference/1,000 PY (95% CI)				ratio (95% CI)
Overall	28,847	157 (9.0)	129 (6.9)		•	2.13 (0.28, 3.97)			1.30 (1.03, 1.6
Age ≥75 years	10,836	84 (13.4)	70 (10.2)		•	3.19 (-0.55, 6.92)		-	1.32 (0.96, 1.8
Age <75 years	17,765	69 (6.3)	59 (5.0)		•	1.28 (-0.67, 3.23)			1.27 (0.89, 1.8
Male	15,959	51 (5.1)	33 (3.2)		•	1.98 (0.21, 3.76)			1.63 (1.05, 2.5
Female	12,547	107 (14.7)	99 (12.2)		•	2.44 (-1.24, 6.12)			1.20 (0.91, 1.5
CVD	16,918	107 (10.9)	86 (8.2)		•	2.76 (0.06, 5.46)		-	1.34 (1.00, 1.7
No CVD	11,665	48 (6.4)	51 (6.3)		+	0.15 (-2.36, 2.65)	-	÷	1.03 (0.69, 1.5
Heart Failure	7,173	49 (12.4)	38 (9.0)		•	3.39 (-1.09, 7.87)		.	1.31 (0.85, 2.0
No HF	21,428	102 (7.6)	87 (6.0)		•	1.60 (-0.35, 3.55)		-	1.28 (0.96, 1.7
Metformin	11,609	54 (7.2)	40 (5.2)		•	2.01 (-0.52, 4.53)		+•-	1.37 (0.90, 2.0
No Metformin	16,862	101 (10.3)	79 (7.3)		•	2.98 (0.40, 5.56)		-	1.39 (1.03, 1.8
Insulin	7,358	44 (10.2)	35 (7.3)		•	2.90 (-0.98, 6.78)		+-	1.43 (0.91, 2.2
No Insulin	21,201	113 (8.7)	99 (7.2)		•	1.51 (-0.64, 3.66)		-	1.21 (0.92, 1.5
Sulfonylurea	11,058	62 (8.8)	54 (7.2)		•	1.59 (-1.32, 4.49)			1.23 (0.85, 1.3
No Sulfonylurea	17,483	93 (9.1)	92 (8.4)	_	+	0.68 (-1.85, 3.21)	-	•	1.07 (0.80, 1.4
					 .	i .		1 1	
				-20	0 20 40		0.5	1 2	4
			Favor	rs SGLT2i	Favors GLP-1RA	Favors	SGLT2i	Favors	GLP-1RA
3 Genital infection	ns	SGLT2i	GLP-1RA			SGLT2i vs GLP	-1RA		

Population	Number of persons/arm	Number (IR/1,0	of events 100 PY)	Incide	ence rate	differend	ce/1,000 PY (95% CI)		1	Hazard	ratio	95% CI)
Overall	28,847	1,018 (60.2)	352 (19.0)			-	41.26 (37.06, 45.4	16)				3.08 (2.73, 3.48)
Age ≥75 years	10,836	390 (63.9)	141 (20.8)				43.09 (35.89, 50.3	30)		-	-	2.98 (2.45, 3.63)
Age <75 years	17,765	623 (58.2)	227 (19.3)			-	38.84 (33.62, 44.0	05)		-	-	2.90 (2.49, 3.37)
Male	15,959	357 (36.6)	139 (13.4)				23.26 (18.86, 27.6	56)		-•	-	2.68 (2.21, 3.26)
Female	12,547	660 (94.5)	206 (25.7)			-	68.81 (60.79, 76.8	32)			•	3.52 (3.01, 4.12)
CVD	16,918	574 (60.3)	220 (21.1)			-	39.22 (33.55, 44.8	39)		-	-	2.79 (2.39, 3.26)
No CVD	11,665	445 (61.4)	146 (18.1)			-	43.29 (36.87, 49.3	71)		-	•	3.28 (2.72, 3.95)
Heart Failure	7,173	249 (64.6)	82 (19.5)				45.12 (36.06, 54.1	19)		_	•	3.26 (2.53, 4.19)
No HF	21,428	780 (60.1)	259 (18.1)			-	41.96 (37.20, 46.3	72)		1	•	3.23 (2.80, 3.72)
Metformin	11,609	451 (62.4)	140 (18.5)				43.95 (37.43, 50.4	18)			٠	3.34 (2.77, 4.04)
No Metformin	16,862	585 (61.5)	196 (18.4)			-	43.11 (37.50, 48.3	72)		1	•	3.23 (2.75, 3.80)
Insulin	7,358	256 (61.2)	109 (23.1)			-	38.04 (29.38, 46.3	70)		-+		2.57 (2.05, 3.22)
No Insulin	21,201	761 (60.6)	263 (19.4)			-	41.24 (36.34, 46.3	L4)		- 4		3.04 (2.64, 3.51)
Sulfonylurea	11,058	422 (61.7)	131 (17.5)			-	44.13 (37.53, 50.3	74)		i. I.	•	3.44 (2.83, 4.19)
No sulfonylurea	17,483	619 (62.2)	219 (20.2)	_		-	42.01 (36.42, 47.6	50)		-	-	3.00 (2.57, 3.50)
				гтi				-	-	-		
				-20 0	20	40		0.5	1	2	4	
			Favors S	GLT2i Fa	vors GLP	-1RA	Favors SGLT2i	Favors	GLP-1	RA		

UKA		SGLIZI	GLP-IKA						SGLIZI VS GLF					
Population	Number of persons/arm	Number (IR/1,	r of events .000 PY)	In	cidenc	ce rate d	lifferer	nce/:	1,000 PY (95% CI)			Hazard	l ratio	o (95% CI)
Overall	28,847	59 (3.4)	58 (3.1)		•				0.29 (-0.89, 1.46)		-	-		1.07 (0.74, 1.54
Age ≥75 years	10,836	23 (3.7)	25 (3.6)		٠				0.01 (-2.05, 2.08)		+	_		1.00 (0.56, 1.7)
Age <75 years	17,765	37 (3.3)	25 (2.1)		٠				1.24 (-0.12, 2.60)		÷	•		1.56 (0.94, 2.60
Male	15,959	20 (2.0)	24 (2.3)		•				-0.28 (-1.56, 0.99)	-	•			0.85 (0.47, 1.56
Female	12,547	38 (5.2)	29 (3.6)	_	٠				1.61 (-0.48, 3.71)	_	÷	-		1.42 (0.87, 2.31
CVD	16,918	30 (3.1)	31 (2.9)		•				0.11 (-1.39, 1.62)		+	_		1.03 (0.63, 1.7)
No CVD	11,665	27 (3.6)	19 (2.3)		٠				1.27 (-0.45, 2.99)		÷	•	-	1.54 (0.86, 2.7)
Heart Failure	7,173	18 (4.5)	18 (4.2)		+				0.28 (-2.58, 3.14)	-	•	_		0.95 (0.48, 1.86
No HF	21,428	40 (3.0)	42 (2.9)		•				0.08 (-1.20, 1.35)		•	-		1.02 (0.66, 1.5)
Metformin	11,609	28 (3.7)	23 (3.0)		٠				0.74 (-1.12, 2.59)			—		1.23 (0.71, 2.15
No Metformin	16,862	31 (3.2)	25 (2.3)		٠				0.84 (-0.60, 2.27)		+	•—		1.31 (0.77, 2.24
Insulin	7,358	21 (4.9)	15 (3.1)		٠				1.74 (-0.88, 4.36)		+	•		1.36 (0.69, 2.68
No Insulin	21,201	33 (2.5)	35 (2.5)		•				-0.01 (-1.22, 1.20)	-	÷			0.99 (0.62, 1.60
Sulfonylurea	11,058	21 (3.0)	20 (2.6)		٠				0.31 (-1.41, 2.02)					1.10 (0.59, 2.04
No Sulfonylurea	17,483	39 (3.8)	35 (3.2)		•			-	0.60 (-0.99, 2.20)		-	-		1.08 (0.67, 1.72
					-i-	<u>п</u>	1 1	٦			÷	-		
				-20	0	20	40			0.5	1	2	4	
			↓ Favo	rs SGLT2i	Fa	ivors GL	P-1RA		↓ Favors	SGLT2i	-	Favors	GLP-:	1RA
D LLA		SGLT2i	GLP-1RA						SGLT2i vs GLF	-1RA				

Population	Number of	Number (IR/1	of events	Incidence rate difference	/1,000 PY (95% CI)	Hazard ratio	95% CI)
Overall	28,847	108 (6.2)	70 (3.7)		2.46 (1.00, 3.92)	i	1.65 (1.22, 2.23
Age ≥75 years	10,836	36 (5.7)	18 (2.6)	•	3.10 (0.88, 5.33)		2.39 (1.32, 4.32
Age <75 years	17,765	70 (6.3)	50 (4.2)	•	2.13 (0.24, 4.02)		1.49 (1.04, 2.15
Male	15,959	78 (7.9)	53 (5.1)	•	2.79 (0.58, 5.01)		1.54 (1.09, 2.19
Female	12,547	29 (4.0)	15 (1.8)	•	2.11 (0.40, 3.83)	—	1.99 (1.06, 3.75
CVD	16,918	86 (8.8)	57 (5.4)	•	3.36 (1.03, 5.69)	-•	1.61 (1.15, 2.25
No CVD	11,665	22 (2.9)	15 (1.8)	•	1.10 (-0.45, 2.64)		1.40 (0.70, 2.83
Heart Failure	7,173	41 (10.3)	19 (4.5)		5.84 (2.10, 9.59)		2.29 (1.32, 3.97
No HF	21,428	68 (5.1)	56 (3.9)	•	1.20 (-0.38, 2.78)	+• -	1.29 (0.90, 1.85
Metformin	11,609	39 (5.2)	28 (3.7)	•	1.56 (-0.57, 3.69)	∔ •	1.41 (0.86, 2.31
No Metformin	16,862	68 (6.9)	47 (4.4)	•	2.57 (0.50, 4.64)		1.56 (1.08, 2.27
Insulin	7,358	52 (12.1)	27 (5.7)		6.47 (2.55, 10.40)		2.10 (1.31, 3.37
No Insulin	21,201	58 (4.5)	41 (3.0)	•	1.48 (0.01, 2.95)		1.48 (0.99, 2.21
Sulfonylurea	11,058	29 (4.1)	29 (3.8)	+	0.25 (-1.80, 2.29)	—	1.05 (0.63, 1.76
No Sulfonylurea	17,483	77 (7.5)	37 (3.4)	•	4.14 (2.14, 6.15)		2.19 (1.48, 3.25
					Г		
			Favor	-20 0 20 40	Eavors SGIT	2 I Z 4	► R∆

Figure 3. Comparative safety of SGLT2i versus GLP-1RA in subgroups after 1:1 propensity score matching for specific outcomes. (A) Nonvertebral fractures, (B) genital infections, (C) DKA, and (D) lower limb amputations. CVD, cardiovascular disease; HF, heart failure.

patient-years; HR, 0.98; 95% CI, 0.70 to 1.37)⁴ or EMPA-KIDNEY (incidence rate 20.9 versus 19.3 per 1000 patientyears; HR, 1.08; 95% CI, 0.84 to 1.38).44 Although the fracture risk in DAPA-CKD did not reach statistical significance, the relative risk was similar in magnitude to our study (incidence rate 4.0 versus 3.2 per 1000 person-years; risk ratio 1.23; 95% CI, 0.90 to 1.68).3 One Canadian observational study assessed the risk of fractures for SGLT2i versus DPP4i but did not find higher risks for 180-day and 365-day intention-to-treat follow-up analyses, with HRs of 0.95 (95% CI, 0.79 to 1.13) and 0.88 (95% CI, 0.77 to 1.00), respectively.⁴⁵ Although we found higher fracture risks in as-treated analyses, these risks diminished in 180-day and 365-day intention-to-treat analyses. However, intention-to-treat analyses often lead to substantial exposure misclassification in observational studies, which typically bias findings toward the null and may falsely miss safety signals. The choice of comparator may also explain the discrepant findings. On the one hand, using DPP4i as the comparator group may increase confounding because these drugs have been shown not to influence cardiovascular or kidney outcomes and were prescribed in our study to older individuals with lower kidney function. On the other hand, GLP-1RA may be preferentially prescribed to more obese individuals, which may protect against hip fractures.⁴⁶ Therefore, our findings need to be replicated in future large-scale studies in patients with CKD.

The higher risk in genital infections with SGLT2i is consistent with previous trials⁴⁷ and observational studies,³² although the incidence rate in our study is markedly higher than that observed in CREDENCE (94.5 in our study versus 12.6 per 1000 person-years in CREDENCE in the SGLT2i arm among women). Interestingly, we did not observe a higher risk of DKA (HR, 1.07; 95% CI, 0.74 to 1.54). Although CREDENCE found higher DKA risk in the SGLT2i arm (HR, 10.80; 95% CI, 1.39 to 83.65), no increased risk was observed in DAPA-CKD, in which no DKA events occurred in the dapagliflozin arm,⁴ or EMPA-KIDNEY, in which only six events occurred in the empagliflozin arm.44 In our study, only 26% of patients used insulin at baseline, compared with 66% in CREDENCE, and our population also had fewer diabetes-related complications such as retinopathy (18% versus 43%) or neuropathy (36% versus 49%), indicative of less advanced diabetes and potentially a greater proportion of insulinresistant rather than insulin-deficient diabetes phenotypes.

Our study has a number of limitations. First, despite the use of an active comparator design and adjustment for a large number of baseline characteristics through propensity score matching, we cannot rule out potential residual confounding. Nevertheless, laboratory measurements, which were not included in the propensity score, were adequately balanced between the SGLT2i and GLP-1RA groups. This is in line with the findings of a previous study showing that active comparator, new-user designs combined with adjustment for a large number of claims-based confounder proxies can ensure sufficient balance in characteristics that are unmeasured in claims data.⁴⁸ Second, we ascertained CKD using diagnosis codes, which has high specificity but low sensitivity,^{25,49,50} and we did not have data on eGFR or albuminuria for all patients. Our results may therefore be

generalizable to patients with diagnosed and recognized CKD, but not to all patients with an eGFR <60 ml/min per 1.73 m² or those with preserved kidney function and albuminuria. Third, we did not assess safety profiles of individual SGLT2i agents because our study was not powered to study individual agents. Finally, our study had a relatively short follow-up because a substantial proportion of patients discontinued the study medication and were therefore censored; specific reasons for discontinuation were not available in our databases. Nevertheless, the safety outcomes of interest occurred rapidly, within 6 months of follow-up, and our study was large enough to observe rare outcomes that had previously been reported in some but not all clinical trials but with greater precision than could be ascertained in those smaller cohorts.

In conclusion, in this large US cohort study of patients with CKD and type 2 diabetes treated in routine clinical practice, initiation of SGLT2i compared with GLP-1RA was associated with higher risks of lower limb amputations, genital infections, and nonvertebral fractures. The higher risk for lower limb amputations and nonvertebral fractures was not observed when using an alternative comparator, DPP4i. No differences were observed for DKA, hypovolemia, hypoglycemia, and severe UTI. Our study can help inform patient-physician decision making regarding risks and benefits before prescribing SGLT2i in this population but needs to be interpreted in light of its limitations, including residual confounding, short follow-up time, and the use of diagnosis codes to identify patients with CKD.

Disclosures

E. D'Andrea reports employment with and ownership interest in AbbVie Inc. and research funding from Bristol Myers Squibb. E. Patorno reports employment with Brigham and Women's Hospital and Harvard Medical School and is investigator of a research grant to the Brigham and Women's Hospital from Boehringer Ingelheim. D.J. Wexler reports consultancy for Novo Nordisk and serving as a Data Monitoring Committee Member for SOUL and FLOW trials. All remaining authors have nothing to disclose.

Funding

E.L. Fu was supported by Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Rubicon Grant). E. Patorno was supported by a career development grant K08AG055670 from the National Institute on Aging and grants from the Patient Centered Outcomes Research Institute (DB-2020C2-20326) and the Food and Drug Administration (5U01FD007213). J.M. Paik was supported by a grant AR075117 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Acknowledgments

Drs. E.L. Fu and J.M. Paik had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs. E.L. Fu and J.M. Paik are the guarantors. Drs. E.L. Fu and J.M. Paik affirm that the manuscript is an honest, accurate, and transparent account of the study being reported, that no important aspects of the study have been omitted, and that any discrepancies from the study as planned have been explained.

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. This study was approved with waiver of informed consent by the Brigham and Women's Hospital Institutional Review Board.

Author Contributions

Conceptualization: Elvira D'Andrea, Edouard L. Fu, Julie M. Paik, Elisabetta Patorno.

Data curation: Julie M. Paik, Elisabetta Patorno.

Formal analysis: Elvira D'Andrea, Edouard L. Fu.

Funding acquisition: Edouard L. Fu, Elisabetta Patorno.

Investigation: Elvira D'Andrea, Edouard L. Fu, Julie M. Paik, Elisabetta Patorno, Deborah J. Wexler.

Methodology: Elvira D'Andrea, Edouard L. Fu, Julie M. Paik, Elisabetta Patorno.

Project administration: Edouard L. Fu, Julie M. Paik, Elisabetta Patorno.

Resources: Elisabetta Patorno.

Software: Elvira D'Andrea, Edouard L. Fu.

Supervision: Julie M. Paik, Elisabetta Patorno.

Validation: Elvira D'Andrea.

Visualization: Elvira D'Andrea, Edouard L. Fu.

Writing - original draft: Edouard L. Fu.

Writing – review & editing: Elvira D'Andrea, Edouard L. Fu, Julie M. Paik, Elisabetta Patorno, Deborah J. Wexler.

Supplemental Material

This article contains the following supplemental material online at http://links.lww.com/CJN/B653.

Supplemental Table 1. Definitions of inclusion and exclusion criteria. Supplemental Table 2. Outcome definitions.

Supplemental Table 3. Full list of baseline characteristics in patients with CKD and type 2 diabetes, stratified by SGLT2i or GLP-1RA initiation in the pooled cohort.

Supplemental Table 4. Full list of baseline characteristics in patients with CKD and type 2 diabetes, stratified by SGLT2i or GLP-1RA initiation in CDM.

Supplemental Table 5. Full list of baseline characteristics in patients with CKD and type 2 diabetes, stratified by SGLT2i or GLP-1RA initiation in MarketScan.

Supplemental Table 6. Full list of baseline characteristics in patients with CKD and type 2 diabetes, stratified by SGLT2i or GLP-1RA initiation in Medicare.

Supplemental Table 7. Individual SGLT2i and GLP-1RA agents included in the analysis after 1:1 propensity score matching.

Supplemental Table 8. Follow-up and censoring reasons after 1:1 propensity score matching for the outcomes, genital infections and lower limb amputations, overall and stratified by SGLT2i or GLP-1RA initiation.

Supplemental Table 9. Number of events, incidence rates, hazard ratios, and incidence rate differences for safety outcomes, comparing SGLT2i versus GLP-1RA after 1:1 propensity score matching —sensitivity analysis applying a 60-day grace period after treatment discontinuation or switching.

Supplemental Table 10. Number of events, incidence rates, hazard ratios, and incidence rate differences for safety outcomes, comparing SGLT2i versus GLP-1RA after 1:1 propensity score matching—sensitivity analysis applying a 180-day intention-to-treat follow-up.

Supplemental Table 11. Number of events, incidence rates, hazard ratios, and incidence rate differences for safety outcomes, comparing SGLT2i versus GLP-1RA after 1:1 propensity score matching—sensitivity analysis applying a 365-day intention-to-treat follow-up.

Supplemental Table 12. Results from *post hoc* analyses in the 1:1 propensity score–matched cohort, excluding prior fractures and lower limb amputations, or changing the comparator group to DPP-4i.

Supplemental Table 13. Number of events, incidence rates, hazard ratios, and incidence rate differences for different types of nonvertebral fractures, comparing SGLT2i versus GLP-1RA after 1:1 propensity score matching.

Supplemental Figure 1. Overview of study design.

Supplemental Figure 2. Patient flow chart.

Supplemental Figure 3. Propensity score distribution before and after 1:1 propensity score matching, stratified by SGLT2i or GLP-1RA initiation.

Supplemental Figure 4. Comparative safety of SGLT2i versus GLP-1RA in subgroups after 1:1 propensity score matching for the specific outcomes (A) hypovolemia, (B) acute kidney injury, (C) hypoglycemia, and (D) severe urinary tract infections.

References

- 1. American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 11. Chronic kidney disease and risk management: standards of medical care in diabetes-2022. *Diabetes Care*. 2022;45(suppl 1):S175–S184. doi:10.2337/dc22-s011
- Rossing P, Caramori ML, Chan JCN, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. *Kidney Int.* 2022;102(5): 990–999. doi:10.1016/j.kint.2022.06.013
- Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi:10.1056/nejmoa2024816
- Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi:10.1056/nejmoa1811744
- Harris ST, Patorno E, Zhuo M, Kim SC, Paik JM. Prescribing trends of antidiabetes medications in patients with type 2 diabetes and diabetic kidney disease, a cohort study. *Diabetes Care.* 2021; 44(10):2293–2301. doi:10.2337/dc21-0529
- Zhuo M, Li J, Buckley LF, et al. Prescribing patterns of sodiumglucose cotransporter-2 inhibitors in patients with CKD: a crosssectional registry analysis. *Kidney360*. 2022;3(3):455–464. doi: 10.34067/KID.0007862021
- Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. *Clin J Am Soc Nephrol.* 2017;12(12):2032–2045. doi:10.2215/CJN.11491116
- Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–308. doi:10.1681/ASN.2012070718
- Tuttle KR, Cherney DZ. Sodium glucose cotransporter 2 inhibition Heralds a call-to-action for diabetic kidney disease. *Clin J Am Soc Nephrol.* 2020;15(2):285–288. doi:10.2215/ CJN.07730719
- Douros A, Lix LM, Fralick M, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. *Ann Intern Med.* 2020;173(6):417–425. doi:10. 7326/m20-0289
- Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017; 376(23):2300–2302. doi:10.1056/nejmc1701990
- Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17(11):3223–3232. doi:10.1681/ ASN.2005111194
- Fried LF, Biggs ML, Shlipak MG, et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol. 2007;18(1):282–286. doi:10.1681/ASN.2006050546
- Otte J, van Netten JJ, Woittiez AJJ. The association of chronic kidney disease and dialysis treatment with foot ulceration and major amputation. *J Vasc Surg.* 2015;62(2):406–411. doi:10. 1016/j.jvs.2015.02.051
- 15. Freeman A, May K, Frescos N, Wraight PR. Frequency of risk factors for foot ulceration in individuals with chronic kidney

disease. Intern Med J. 2008;38(5):314-320. doi:10.1111/j.1445-5994.2007.01528.x

- McGovern A, Feher M, Munro N, de Lusignan S. Sodium-glucose cotransporter 2 (SGLT2) inhibitor: comparing trial data and real-world use. *Diabetes Ther.* 2017;8(2):365–376. doi:10.1007/s13300-017-0254-7
- Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. *Am J Manag Care.* 2018;24(8 suppl):S138–S145
- Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. *Curr Epidemiol Rep.* 2015; 2(4):221–228. doi:10.1007/s40471-015-0053-5
- Fu EL, van Diepen M, Xu Y, et al. Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them. *Clin Kidney J.* 2021;14(5):1317–1326. doi:10.1093/ckj/sfaa242
- Schneeweiss S, Patorno E. Conducting real-world evidence studies on the clinical outcomes of diabetes treatments. *Endocr Rev.* 2021;42(5):658–690. doi:10.1210/endrev/bnab007
- Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and metaanalysis of randomised trials. *Lancet Diabetes Endocrinol.* 2021; 9(10):653–662. doi:10.1016/s2213-8587(21)00203-5
- 22. Das SR, Everett BM, Birtcher KK, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology solution set oversight committee. *J Am Coll Cardiol.* 2020;76(9):1117–1145. doi:10.1016/j.jacc.2020.05.037
- 23. Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2020;43(2):487–493. doi:10.2337/dci19-0066
- Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2018; 41(12):2669–2701. doi:10.2337/dci18-0033
- Paik JM, Patorno E, Zhuo M, et al. Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data. *Pharmacoepidemiol Drug Saf.* 2022; 31(4):467–475. doi:10.1002/pds.5398
- 31(4):467–475. doi:10.1002/pds.5398
 26. Hawley CE, Lauffenburger JC, Paik JM, Wexler DJ, Kim SC, Patorno E. Three sides to the story: adherence trajectories during the first Year of SGLT2 inhibitor therapy among Medicare beneficiaries. *Diabetes Care*. 2022;45(3):604–613. doi:10.2337/dc21-1676
- Bobo WV, Cooper WO, Epstein RA Jr, Arbogast PG, Mounsey J, Ray WA. Positive predictive value of automated database records for diabetic ketoacidosis (DKA) in children and youth exposed to antipsychotic drugs or control medications: a Tennessee Medicaid Study. *BMC Med Res Methodol.* 2011;11(1):157. doi:10. 1186/1471-2288-11-157
- 28. Newton KM, Wagner EH, Ramsey SD, et al. The use of automated data to identify complications and comorbidities of diabetes: a validation study. *J Clin Epidemiol.* 1999;52(3):199–207. doi:10. 1016/s0895-4356(98)00161-9
- Ray WA, Griffin MR, Fought RL, Adams ML. Identification of fractures from computerized Medicare files. J Clin Epidemiol. 1992;45(7):703–714. doi:10.1016/0895-4356(92)90047-q
- Hudson M, Avina-Zubieta A, Lacaille D, Bernatsky S, Lix L, Jean S. The validity of administrative data to identify hip fractures is high—a systematic review. J Clin Epidemiol. 2013;66(3):278– 285. doi:10.1016/j.jclinepi.2012.10.004
- Waikar SS, Wald R, Chertow GM, et al. Validity of International Classification of Diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol. 2006;17(6): 1688–1694. doi:10.1681/ASN.2006010073
- Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. *Diabetes Obes Metab.* 2019;21(2):434–438. doi:10. 1111/dom.13531
- Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe

urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171(4):248–256. doi:10.7326/m18-3136

- Fralick M, Kim SC, Schneeweiss S, Everett BM, Glynn RJ, Patorno E. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. *BMJ*. 2020;370:m2812. doi:10.1136/bmj.m2812
- Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring frailty in Medicare data: development and validation of a claims-based frailty index. J Gerontol A Biol Sci Med Sci. 2018;73(7):980–987. doi:10.1093/gerona/glx229
- Fu EL, Groenwold RHH, Zoccali C, Jager KJ, van Diepen M, Dekker FW. Merits and caveats of propensity scores to adjust for confounding. *Nephrol Dial Transplant*. 2019;34(10):1629–1635. doi:10.1093/ndt/gfy283
- 37. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. *Commun Stat Simulat Comput.* 2009;38(6): 1228–1234. doi:10.1080/03610910902859574
- Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensityscore matched samples. *Stat Med.* 2009;28(25):3083–3107. doi: 10.1002/sim.3697
- Xu Y, Cheung YB, Lam KF, Tan SH, Milligan P. A simple approach to the estimation of incidence rate difference. *Am J Epidemiol.* 2010;172(3):334–343. doi:10.1093/aje/kwq099
- Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. *Stat Med.* 2007;26(11):2389– 2430. doi:10.1002/sim.2712
- 41. James MT, Grams ME, Woodward M, et al. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury. *Am J Kidney Dis.* 2015;66(4):602–612. doi:10.1053/j.ajkd.2015.02.338
- 42. de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. *Kidney Int.* 2020;98(4):839–848. doi:10.1016/j.kint.2020.06.024
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi:10.1056/nejmoa1611925
- The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–127. doi:10.1056/NEJMoa2204233
- Cowan A, Jeyakumar N, Kang Y, et al. Fracture risk of sodium-glucose cotransporter-2 inhibitors in chronic kidney disease. *Clin J Am Soc Nephrol.* 2022;17(6):835–842. doi:10.2215/CJN.16171221
- 46. Tang X, Liu G, Kang J, et al. Obesity and risk of hip fracture in adults: a meta-analysis of prospective cohort studies. *PLoS One*. 2013;8(4):e55077. doi:10.1371/journal.pone.0055077
 47. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose co-
- Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. *BMJ*. 2021;372:m4573. doi:10.1136/bmj.m4573
- Patorno E, Gopalakrishnan C, Franklin JM, et al. Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. *Diabetes Obes Metab.* 2018;20(4):974–984. doi:10.1111/dom.13184
- Grams ME, Plantinga LC, Hedgeman E, et al. Validation of CKD and related conditions in existing data sets: a systematic review. *Am J Kidney Dis.* 2011;57(1):44–54. doi:10.1053/j.ajkd.2010.05.013
- Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. *Am J Kidney Dis.* 2005; 46(2):225–232. doi:10.1053/j.ajkd.2005.04.029
- Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749–759. doi: 10.1016/j.jclinepi.2010.10.004

Received: November 15, 2022 Accepted: February 14, 2023 Published Online Ahead of Print: February 24, 2023

See related editorial, "Relative and Absolute Risks of Adverse Events with Real-World Use of SGLT2 Inhibitors in CKD," on pages 557–559.